Vaccines and Vaccine Adjuvants for Infectious Diseases and Autoimmune Diseases
1. Microbes in Health and Disease
2. Infectious Diseases
3. Autoimmune Diseases
4. Vaccine Adjuvants
Conflicts of Interest
References
- Martino, C.; Dilmore, A.H.; Burcham, Z.M.; Metcalf, J.L.; Jeste, D.; Knight, R. Microbiota succession throughout life from the cradle to the grave. Nat. Rev. Microbiol. 2022, 20, 707–720. [Google Scholar] [CrossRef]
- Hou, K.; Wu, Z.X.; Chen, X.Y.; Wang, J.Q.; Zhang, D.; Xiao, C.; Zhu, D.; Koya, J.B.; Wei, L.; Li, J.; et al. Microbiota in health and diseases. Signal Transduct. Target. Ther. 2022, 7, 135. [Google Scholar] [CrossRef]
- Pollard, A.J.; Bijker, E.M. A guide to vaccinology: From basic principles to new developments. Nat. Rev. Immunol. 2021, 21, 83–100. [Google Scholar] [CrossRef] [PubMed]
- Excler, J.L.; Saville, M.; Berkley, S.; Kim, J.H. Vaccine development for emerging infectious diseases. Nat. Med. 2021, 27, 591–600. [Google Scholar] [CrossRef] [PubMed]
- Wagner, A.; Weinberger, B. Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives. Front. Immunol. 2020, 11, 717. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ng, S.C.; Peng, Y.; Zhang, L.; Mok, C.K.; Zhao, S.; Li, A.; Ching, J.Y.; Liu, Y.; Yan, S.; Chan, D.L.S.; et al. Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse events. Gut 2022, 71, 1106–1116. [Google Scholar] [CrossRef] [PubMed]
- Balhuizen, M.D.; Veldhuizen, E.J.A.; Haagsman, H.P. Outer Membrane Vesicle Induction and Isolation for Vaccine Development. Front. Microbiol. 2021, 12, 629090. [Google Scholar] [CrossRef]
- Wang, T.; Mo, L.; Ou, J.; Fang, Q.; Wu, H.; Wu, Y.; Nandakumar, K.S. Proteus mirabilis Vesicles Induce Mitochondrial Apoptosis by Regulating miR96-5p/Abca1 to Inhibit Osteoclastogenesis and Bone Loss. Front. Immunol. 2022, 13, 833040. [Google Scholar] [CrossRef]
- Kashyap, D.; Panda, M.; Baral, B.; Varshney, N.; Sajitha, R.; Bhandari, V.; Parmar, H.S.; Prasad, A.; Jha, H.C. Outer Membrane Vesicles: An Emerging Vaccine Platform. Vaccines 2022, 10, 1578. [Google Scholar] [CrossRef]
- Scher, J.U.; Sczesnak, A.; Longman, R.S.; Segata, N.; Ubeda, C.; Bielski, C.; Rostron, T.; Cerundolo, V.; Pamer, E.G.; Abramson, S.B.; et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. eLife 2013, 2, e01202. [Google Scholar] [CrossRef]
- Houen, G.; Trier, N.H. Epstein-Barr Virus and Systemic Autoimmune Diseases. Front. Immunol. 2020, 11, 587380. [Google Scholar] [CrossRef] [PubMed]
- Smatti, M.K.; Cyprian, F.S.; Nasrallah, G.K.; Al Thani, A.A.; Almishal, R.O.; Yassine, H.M. Viruses and Autoimmunity: A Review on the Potential Interaction and Molecular Mechanisms. Viruses 2019, 11, 762. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Maddur, M.S.; Vani, J.; Lacroix-Desmazes, S.; Kaveri, S.; Bayry, J. Autoimmunity as a predisposition for infectious diseases. PLoS Pathog. 2010, 6, e1001077. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Agmon-Levin, N.; Paz, Z.; Israeli, E.; Shoenfeld, Y. Vaccines and autoimmunity. Nat. Rev. Rheumatol. 2009, 5, 648–652. [Google Scholar] [CrossRef]
- Dzhambazov, B.; Nandakumar, K.S.; Kihlberg, J.; Fugger, L.; Holmdahl, R.; Vestberg, M. Therapeutic vaccination of active arthritis with a glycosylated collagen type II peptide in complex with MHC class II molecules. J. Immunol. 2006, 176, 1525–1533. [Google Scholar] [CrossRef] [Green Version]
- Park, Y.K.; Jung, S.; Park, S.H. Induction of tolerance against the arthritogenic antigen with type-II collagen peptide-linked soluble MHC class II molecules. BMB Rep. 2016, 49, 331–336. [Google Scholar] [CrossRef] [Green Version]
- Shakya, A.K.; Nandakumar, K.S. Antigen-Specific Tolerization and Targeted Delivery as Therapeutic Strategies for Autoimmune Diseases. Trends Biotechnol. 2018, 36, 686–699. [Google Scholar] [CrossRef]
- Aaby, P.; Benn, C.S.; Flanagan, K.L.; Klein, S.L.; Kollmann, T.R.; Lynn, D.J.; Shann, F. The non-specific and sex-differential effects of vaccines. Nat. Rev. Immunol. 2020, 20, 464–470. [Google Scholar] [CrossRef]
- Ishii, K.J.; Akira, S. Toll or toll-free adjuvant path toward the optimal vaccine development. J. Clin. Immunol. 2007, 27, 363–371. [Google Scholar] [CrossRef]
- Reed, S.G.; Tomai, M.; Gale, M.J., Jr. New horizons in adjuvants for vaccine development. Curr. Opin. Immunol. 2020, 65, 97–101. [Google Scholar] [CrossRef]
- Shakya, A.K.; Nandakumar, K.S. Applications of polymeric adjuvants in studying autoimmune responses and vaccination against infectious diseases. J. R. Soc. Interface 2013, 10, 20120536. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Nandakumar, K.S. Vaccines and Vaccine Adjuvants for Infectious Diseases and Autoimmune Diseases. Vaccines 2023, 11, 202. https://doi.org/10.3390/vaccines11020202
Nandakumar KS. Vaccines and Vaccine Adjuvants for Infectious Diseases and Autoimmune Diseases. Vaccines. 2023; 11(2):202. https://doi.org/10.3390/vaccines11020202
Chicago/Turabian StyleNandakumar, Kutty Selva. 2023. "Vaccines and Vaccine Adjuvants for Infectious Diseases and Autoimmune Diseases" Vaccines 11, no. 2: 202. https://doi.org/10.3390/vaccines11020202
APA StyleNandakumar, K. S. (2023). Vaccines and Vaccine Adjuvants for Infectious Diseases and Autoimmune Diseases. Vaccines, 11(2), 202. https://doi.org/10.3390/vaccines11020202